Jiangsu Hengrui Pharmaceuticals Co., Ltd./ADR

Over the past 90 days, Jiangsu Hengrui Pharmaceuticals (JNGHF) has recorded zero cyber incidents and zero red-flag 8-K filings related to bankruptcy, delisting, restatement, or officer departures. This clean recent window does not preclude material risks—our 90-day ingestion captures only the immediate horizon, and pharmaceutical ADRs face sector-specific pressures including financing cycles, regulatory headwinds, and equity dilution patterns. The full $49 Report extends analysis across 12 months of SEC filings, applies our dilution risk scoring framework, contextualizes all 8-K events, and layers AI risk signals specific to China-listed pharma structures and ADR mechanics. The full $49 Report adds historical depth, quantified dilution trajectories, and forward-looking risk signals that a snapshot cannot.